Zyprexa Papers

These documents are linked to the book – The Zyprexa Papers:

A Memorandum Final Judgment Order & Injunction 07504

A Texas lawsuit

Adverse Effects 1998

Alan and Charles

APA 2001 – the competition

Article in Lancet

Beasley email 2

Beasley presentation

Berenson Zyprexa

Betting_the_farm

biol psych review

Bipolar APA 2002

Bipolar APA 2003

Bipolar disorder 2002 a

Bipolar Primary Care A & C

Bipolar Primary Care

Bipolar Strategy.ppt TM

Bipolar Tollefson 1997

Blood Results 2

Brand Architecture

Brand Decliners

Brand Leadership

Brand Promise 2000

Brand Promise and Weight

Brand Segmentation

Brand Segmentation 2

Brand Strategy 2003

Brand Strategy 2003 A

Breier Patients First

Cavazzoni Lilly Diabetes Study

Challenge Dechallenge

Citrome Article

Diabetes and DKA

Diabetes and S.ppt TM

Diabetes and Schiz 2001 1

Diabetes Antipsychotic Study

Diabetes Antipsychotics USA 2001

Diabetes Crisis 2002

Diabetes Crisis 2002 FDA

Diabetes Crisis 2003 FDA

Diabetes Email 2

Diabetes Email 3

Diabetes Email 4

Diabetes Email 5

Diabetes for Reps 2002

Diabetes Globally 2000

Diabetes in Mental Illness – Koller

Diabetes Key Messages 2002

Diabetes Label 2002

Diabetes Positioning

Diabetes Reps 4

Diabetes Strategy 2001

Diabetes Strategy 2002

Diabetes Strategy 2003

Donna and Diabetes

Donna FAOC Donna

Doraiswamy Letter

Early Development

Elderly Psychosis

Email Diabetes 4

Email Diabetes 6

Email MGH Meeting

Email Primary Care

Email Primary Care 2

Emotional Level

Endocrine Advisory Board

Endocrine Consult 2

Endocrinologists

FDA Canada Label

FDA Diabetes 2003

FDA European Label

FDA Katz Phone Call

Focus Group 1995

Focus Group 2002

Focus Group 2003

Focus Group Diabetes Newcomer

Framingham Heart

GPRD Antipsychotics and Diabetes 2001

HD for Reps 2001

HD Labelling 2003

HD Literature 2001

HD Strategy 2001

HD Strategy 2001 A

HDL Literature 2002

HDL Literature 2002 A

HDL Literature 2003

History Zyprexa Struther

Hyperglycemia 2001

Hyperglycemia Label 2003

Key Messages on Side Effects

Labels Diabetes

Lindenmayer Trial 2002

Marketplace Plan Helen

Mcneely Article

Media Diabetes 2000

Metabolic 2003 A

Metabolic Risperdal et al

Metabolic Syndrome

Nasrallah Anti Zyprexa

National Sales 2001

Newcomer 1 Diabetes

Newcomer 02-03-04

Newcomer 05-03-04

Newcomer 07-08-02

Newcomer 08-07-02 Rosack

Newcomer 09-08-02 Fear

Newcomer 9 Rosack

Newcomer 15-06-02

Newcomer 17-10-03 Rosack2

Newcomer 18-02-02 Comment on Talk

Newcomer 19-09-01 Diabetes

Newcomer 20-02-04 Good

Newcomer 20-06-02

Newcomer Talk 6

Off_Label_Primarycare

Off-Label Strategy

Olanzapine and Weight 1999

Olanzapine Lifeplan

Perceptions of Diabetes and AP

Physician Strategy and Weight

Primary Care 2 David

Primary Care 3 Off Label

Primary Care 5 1999

Primary Care 6 2000 Viva Zyprexa

Primary Care 2000

Primary Care 2001

Primary Care 2002

Primary Care and Weight – Own the Issue

Primary Care Backlash

Primary Care Launch 2000

Primary Care Launch

Primary Care Mood

Primary Care Mood and Diabetes

Primary Care Mood Patients

Primary Care Mood Patients 2

Primary Care Strategy 3

Primary_Care_Oppty

Product Plan 2001

Psych Segments.ppt TM

Regulatory History

Regulatory History 2

Safety Letter to Docs

Safety Policy 2002

Saunders Statement

Schiz Puerto Rico 1995

Schiz Weight 2003

Segmentation Email

Silverman on Antipsychotics

SPP Action Plan

Stahl Metabolic 1

Suicide et al Reports

Tracking Study 2000

Turnbull Letter

Turnbull Letter 2

Ventura Letter 1

Versus Risperdal 1998

Versus Risperdal 2001

Veterans Diabetes

Weight 2003 Issues Focus

Weight and Diabetes

Weight and Market

Weight and Olanzapine Draft Article

Weight Change 2000

Weight Gain 2000

Weight Gain Canada 2000

Weight Gain Rep Strategy Ireland

Weight Gain Strategy 1998

Weight Linguistics

Weight Lit 2003

Weight Literature 2000

Zyprexa Approval Call

Zyprexa Business 2002

Zyprexa Confidential Order PO

Zyprexa For Reps 2003

Zyprexa Market 1995